Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations.

Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations.

The employment of anti-epidermal growth factor receptor (EGFR) antibodies represents a backbone of the therapeutic options for the treatment of metastatic colorectal cancer (mCRC). However, this therapy is poorly effective or ineffective in unselected patients. Mutations in KRAS, BRAF and PIK3CA gen...

Full description

Bibliographic Details
Main Authors: Giovanni Brandi, Simona Tavolari, Francesco De Rosa, Stefania Di Girolamo, Valentina Agostini, Maria Aurelia Barbera, Giorgio Frega, Guido Biasco
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3404056?pdf=render

Internet

http://europepmc.org/articles/PMC3404056?pdf=render

Similar Items